kabutan

ZERIA PHARMA, First Half Ordinary Profit Decreases by 67%, Jul-Sep Ordinary Profit Decreases by 60%

Wed Nov 5, 2025 4:00 pm JST Earnings

4559 ZERIA PHARMACEUTICAL CO.,LTD. 【J-GAAP】

Earnings Report

ZERIA PHARMACEUTICAL CO.,LTD. <4559> [TSE Prime] announced its financial results after the market closed on November 5th (16:00). The consolidated ordinary profit for the cumulative second quarter of the fiscal year ending March 2026 (April to September) significantly dropped 66.6% from the same period last year to 2.65 billion yen. Progress toward the full-year plan of 12.0 billion yen was 22.1%, also falling below the five-year average of 57.6%.

Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit for the October to March period (second half) is expected to expand 91.0% from the same period last year, reaching 9.34 billion yen.

In the most recent three-month period, from July to September (2Q), the consolidated ordinary profit significantly dropped to 0.99 billion yen, a 60.1% decrease compared to the same period last year. The operating profit margin decreased from 12.0% in the same period last year to 10.4%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Sep, 2023 36,678 5,327 5,495 5,396 122.4 64.5 Nov 1, 2023 J-GAAP
Apr - Sep, 2024 42,422 6,459 7,949 6,061 137.5 61.9 Nov 6, 2024 J-GAAP
Apr - Sep, 2025 39,960 3,641 2,656 1,737 39.4 22.1 Nov 5, 2025 J-GAAP
YoY -5.8% -43.6% -66.6% -71.3% -71.3%

First Half Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2025 Guidance 39,960 3,640 2,650 1,730 39.3 24 Oct 31, 2025 J-GAAP
Apr - Sep, 2025 Results 39,960 3,641 2,656 1,737 39.4 24 Nov 5, 2025 J-GAAP
Revision Rate 0.0% +0.0% +0.2% +0.4% +0.4%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 44,889 5,738 4,891 3,875 87.9 24 May 8, 2025 J-GAAP
Oct - Mar, 2025 Guidance 50,040 8,359 9,344 7,763 176.1 24 Nov 5, 2025 J-GAAP
YoY +11.5% +45.7% +91.0% +100.3% +100.3%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 75,725 9,621 8,513 7,731 175.4 44 May 9, 2024 J-GAAP
Mar, 2025 87,311 12,197 12,840 9,936 225.4 47 May 8, 2025 J-GAAP
Mar, 2026 Guidance 90,000 12,000 12,000 9,500 215.5 48 May 8, 2025 J-GAAP
YoY +3.1% -1.6% -6.5% -4.4% -4.4%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jul - Sep, 2024 20,967 2,520 2,490 1,849 42.0 12.0 Nov 6, 2024 J-GAAP
Oct - Dec, 2024 22,351 3,787 2,712 2,165 49.1 16.9 Feb 5, 2025 J-GAAP
Jan - Mar, 2025 22,538 1,951 2,179 1,710 38.8 8.7 May 8, 2025 J-GAAP
Apr - Jun, 2025 19,489 1,520 1,662 1,090 24.8 7.8 Aug 5, 2025 J-GAAP
Jul - Sep, 2025 20,471 2,121 994 647 14.7 10.4 Nov 5, 2025 J-GAAP
YoY -2.4% -15.8% -60.1% -65.0% -65.0%

Related Articles